SIIC Salud





Ayuda
 

Comprar este informe
Extensión: 6.47 páginas impresas en papel A4 páginas impresas en papel A4

file05.gif (1491 bytes)
Art�culos seleccionados para su compra

Casos clínicos

PROBABLE ASOCIACIóN DE LOS INHIBIDORES DE LA TIROSINA QUINASA CON LA PERSISTENCIA DE CLONES ABERRANTES CON CROMOSOMA FILADELFIA NEGATIVO

Se describe el caso de un paciente con leucemia mieloide crónica que, durante el tratamiento con inhibidores de la tirosina quinasa de primera y segunda generación, presenta múltiples clones con anomalías cromosómicas.
Autor
Adriana Zamecnikova
Columnista Experta de SIIC
Institución del autor
Kuwait Cancer Control Center, Shuwaikh, Kuwait

Artículos publicados por Adriana Zamecnikova
link.gif
Profundizar versión original en inglés
link.gif
Profundizar versión original traducida

Clasificación en siicsalud
Artículos originales > Expertos del Mundo >
página  http://siicsalud.com/dato/casiic.php/115090

Especialidades
 rarrowsm.gif He.gif rarrowsm.gif On.gif flecha_roja.gif   flecha_roja.gif   flecha_roja.gif   flecha_roja.gif   flecha_roja.gif 
Primera edición en siicsalud
31 de agosto, 2011

Bibliografía del caso clínico
1. Quintas-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood 113:1619-1630, 2009.
2. Konig H, Holtz M, Modi H, Manley P, Holyoake TL, Forman SJ, et al. Enhanced BCR-ABL kinase inhibition does not result in increased inhibition of downstream signaling pathways or increased growth suppression in CML progenitors. Leukemia 22 4:748-55, 2008.
3. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 112(13):4808-4817, 2008.
4. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23(6):1054-61, 2009.
5. Branford S. Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice. Hematology 1:376-383, 2007.
6. Bumm T, Muller C, Al-Ali HK, Krohn K, Shepherd P, Schmidt E, et al. Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority. Blood 101(5):1941-9, 2003.
7. Espinet B, Oliveira AC, Boque C, Domingo A, Alonso E, Sole F. Clonal cytogenetic abnormalities in patients with chronic myeloid leukemia in complete cytogenetic response to imatinib mesylate. Haematologica 90:556-558, 2005.
8. Deininger MW, Cortes J, Paquette R, Park B, Hochhaus A, Baccarani M et al. The prognosis for patients with chronic myeloid leukemia who have clonal cytogenetic abnormalities in philadelphia chromosome-negative cells. Cancer 110:1509-1519, 2007.
9. Loriaux M, Deininger M. Clonal cytogenetic abnormalities in Philadelphia chromosome negative cells in chronic myeloid leukemia patients treated with imatinib. Leuk Lymphoma 45:2197-2203, 2004.
10. Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia negative cells during imatinib treatment of Philadelphia positive chronic myeloid leukemia. Leukemia 18:1340-1346, 2004.
11. ISCN 1995: an international system for human cytogenetic nomenclature (1995). Mitelman F, editor. Basel: S. Karger, 1995.
12. Zámeníkova A, Al-Bahar S Pandita R. Trisomy 6 in a CML patient receiving imatinib mesylate therapy. Leuk Res 32:1454-1457, 2008.
13. Goldberg SL, Madan RA, Rowley SD, Pecora AL, Hsu JW, Tantravahi R. Myelodysplastic subclones in chronic myeloid leukemia: implications for imatinib mesylate therapy. Blood 101:781-781, 2003.
14. Baldazzi C, Luatti S, Marzocchi G, Stacchini M, Gamberini C, Castagnetti F, et al. Emergence of clonal chromosomal abnormalities in Philadelphia negative hematopoiesis in chronic myeloid leukemia patients treated with nilotinib after failure of imatinib therapy. Leuk Res 33(12):e218-20, 2009.
15. Fabarius A, Haferlach C, Müller MC, Erben P, Lahaye T, Giehl M et al. Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure. Haematologica 92:834, 2007.
16. Kovitz C, Kantarjian H, Garcia-Manero G, Abruzzo LV, Cortes J. Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia. Blood 108:2811-2813, 2006.
17. Navarro JT, Feliu E, Grau J, Espinet B, Colomer D, Ribera JM et al. Monosomy 7 with severe myelodysplasia developing during imatinib treatment of Philadelphia-positive chronic myeloid leukemia: two cases with a different outcome. Am J Hematol 82:849-851, 2007.
18. Jabbour E, Kantarjian HM, Abruzzo LV, O'Brien S, Garcia-Manero G, Verstovsek S et al. Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood 110:2991-2995, 2007.
19. Cervetti G, Carulli G, Galimberti S, Azzarà A, Buda G, Orciuolo E et al. Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia. Leuk Res 32:194-195, 2008.
20. LeMarbre G, Schinstock C, Hoyer R, Krook J, Tefferi A. Late onset aplastic anemia during treatment of chronic myeloid leukemia with imatinib mesylate. Leuk Res 31:414-415, 2007.
21. Moormeier JA, Rubin CM, Le Beau MM, Vardiman JW, Larson RA. Trisomy 6: A recurring cytogenetic abnormality associated with marrow hypoplasia. Blood 77:1397-1401, 1991.
22. Yilmaz Y, Klein R, Qumsiyeh MB. Trisomy 6 acquired in lymphoid blast transformation of chronic myelocytic leukemia with t(9;22) Cancer Genet Cytogenet 145:86-87, 2003.
23. Giehl FM, Rebacz B, Kramer A, Frank O, Haferlach C, Duesberg P, Hehlmann R, Seifarth W, Hochhaus A. Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica 93:1145-1154, 2008. 24. Fabarius A, Giehl M, Frank O, Duesberg P, Hochhaus A, Hehlmann R et al. Induction of centrosome and chromosome aberrations by imatinib in vitro. Leukemia 19:1573-1578, 2005.
25. Fabarius A, Giehl M, Frank O, Spiess B, Zheng C, Müller MC. Centrosome aberrations after nilotinib and imatinib treatment in vitro are associated with mitotic spindle defects and genetic instability. Br J Haematol 138:369-373, 2007.
 
Artículos publicados por el autor (selección)
Al- Bahar S, Zámecníkova A. Frequency and type of chromosomal abnormalities in childhood ALL patients in Kuwait: A six-year retrospective study. Med Princ Pract 19:176-181, 2010

Zamecnikova A . Targetting the BCR-ABL tyrosine kinase in chronic myeloid leukemia as a model of rational drug dsign in cancer. Expert Reviews of Hematology 3:45-56, 2010

Al-Bahar S, Zámecníkova A, Pandita R. A novel variant translocation t(6;8;21)(p21;q22;q22) leading to AML/ETO fusion in acute myeloid leukemia. Gulf Journal of Oncology. 5:56-59, 2008

Zámecníkova A, Al- Bahar S. Simultaneous occurrence of MLL and RARA rearrangements in a pediatric acute lymphoblastic leukemia patient. Pediatric Blood & Cancer 52:671-674, 2009

Está expresamente prohibida la redistribución y la redifusión de todo o parte de los contenidos de la Sociedad Iberoamericana de Información Científica (SIIC) S.A. sin previo y expreso consentimiento de SIIC.

anterior.gif (1015 bytes)


Suscripción a siicsalud


Bienvenidos a siicsalud

Acerca de SIIC     Estructura de SIIC

Sociedad Iberoamericana de Información Científica (SIIC)
Av. Belgrano 430, (C1092AAR), ciudad de Buenos Aires, Argentina
Tel: +54 11 4342 4901
Casilla de Correo 2568, (C1000WAZ) Correo Central, ciudad de Buenos Aires
Copyright siicsalud© 1997-2017, Sociedad  Iberoamericana de Información Científica (SIIC)
ISSN siicsalud: 1667-9008
ua4711
Mensajes a SIIC